<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377271</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000848-14</org_study_id>
    <nct_id>NCT02377271</nct_id>
  </id_info>
  <brief_title>ENDOTHELION Study Group: Effect of Bosentan in NAION Patients</brief_title>
  <acronym>ENDOTHELION</acronym>
  <official_title>Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after&#xD;
      glaucoma in the population aged over 50 years. The visual prognosis of the condition is&#xD;
      unfavorable in the great majority of cases, with significant effects on the visual field and&#xD;
      vision. The severity of the unilateral condition is also associated with bilateralization in&#xD;
      15% at 5 years. There is no effective treatment for the acute phase of the disease or to&#xD;
      reduce the rate of bilateralization. In this context, it is essential to develop new&#xD;
      therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve&#xD;
      damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of our study will be to compare the treatment with bosentan to placebo for&#xD;
      8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual&#xD;
      acuity, visual field). The primary endpoint will be the improvement of the visual field, a&#xD;
      major criterion of the affected visual function in this disease.&#xD;
&#xD;
      The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the&#xD;
      effectiveness of drug treatment in the absence of continuous positive airway pressure (set up&#xD;
      after three months if necessary, feasible confounding factor for the evaluation of results ),&#xD;
      the period of three months is sufficient to assess the anatomical and functional recovery&#xD;
      (disappearance of papilledema).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>automated visual field (Humphrey 30-2 SITA-standard)</measure>
    <time_frame>3 month</time_frame>
    <description>Humphrey 30-2 SITA-standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity (ETDRS scale)</measure>
    <time_frame>6, 12 and 24 month</time_frame>
    <description>ETDRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optic nerve fiber layer thickness</measure>
    <time_frame>3, 6, 12 and 24 month</time_frame>
    <description>OCT measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field for healthy eye and NAION eye</measure>
    <time_frame>3, 6, 12 and 24 month</time_frame>
    <description>Humphrey 30-2 and 60-4 sita-standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker and prepro-endothelin dosing</measure>
    <time_frame>3 month</time_frame>
    <description>RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>automated visual field for controlateral eye</measure>
    <time_frame>24 month</time_frame>
    <description>Humphrey 30-2 sita-standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 and 12 month</time_frame>
    <description>VFQ-25</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drug , twice a day, during eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>treatment by bosentan or placebo is randomized , 125 mg twice a day</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>treatment by bosentan or placebo is randomized</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non arteritic ischemic optic neuropathy (NAION) with onset &lt; 21 days with or without&#xD;
             sleep apnea&#xD;
&#xD;
          -  Negative pregnancy test and use of a effective conraceptive methode for non-menauposal&#xD;
             wemen&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Person affiliated to social security&#xD;
&#xD;
          -  Patient with systolic pressure ≥ 100 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, parturient or nursing woman&#xD;
&#xD;
          -  Woman of child bearing potential without an effective contracptive method (use of&#xD;
             hormonal contraception only is not considered effective)&#xD;
&#xD;
          -  Other intercurrent ocular pathology, acute or chronic&#xD;
&#xD;
          -  Simultaneaous bilateral NAION, ≤ 1 month&#xD;
&#xD;
          -  Signs of another inflammatory neuropathy (Horton disease, optical nevritis,&#xD;
             inflammatory optical neuropathy history)&#xD;
&#xD;
          -  Signs of a retinal pathology&#xD;
&#xD;
          -  Signs of a neuroretinis&#xD;
&#xD;
          -  Patient with systolic pressure &lt; 100 mmHg&#xD;
&#xD;
          -  Patient with orthostatic hypotension&#xD;
&#xD;
          -  Neurologic history : vascular or tumoral&#xD;
&#xD;
          -  Systemic inflammatory pathology&#xD;
&#xD;
          -  Known allergy to Bosentan&#xD;
&#xD;
          -  Moderate to severe hepatic failure&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 30 ml/min/1,73 m2&#xD;
&#xD;
          -  Patient treated with drugs which efficacy can be lowered by CYP450, CYP2C9, CYP3A4 and&#xD;
             CYP 2C19 activation&#xD;
&#xD;
          -  Patient treated with amiodarone&#xD;
&#xD;
          -  Patient treated with forbidden drugs for the study&#xD;
&#xD;
          -  Patient treated with systemic corticotherapy&#xD;
&#xD;
          -  Subject under juridic protection or not able to give informed consent, subject&#xD;
             deprived of liberty&#xD;
&#xD;
          -  Subject participaing to another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <email>CChiquet@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baidi Zineb, PhD</last_name>
    <phone>+33 476766660</phone>
    <email>ZBaidi@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan MILEA, MD</last_name>
      <phone>0241353274</phone>
      <email>dmilea@free.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie LERUEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric GAGNADOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascaline PRIOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Bénédicte ROUGIER, MD</last_name>
      <phone>05 57 82 12 16</phone>
      <email>marie-benedicte.rougier@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François KOROBELNIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre PHILIP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EMILIE TOURNAIRE MARQUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Arthur MICOULAUD FRENCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CHIQUET, MD</last_name>
      <phone>04 76 76 55 16</phone>
      <email>CChiquet@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florent APTEL, MD</last_name>
      <phone>04 76 76 55 48</phone>
      <email>faptel@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Paul ROMANET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis PEPIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud TAMISIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAUNOIS-ROLLINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand TOUSSAINT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier ORMEZZANO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole BURILLON, MD</last_name>
      <phone>0472116217</phone>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lucie ABOUAF, MD</last_name>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric GORMAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain BECCAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophtalmological fondation of Rothschild + Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine VIGNAL, MD</last_name>
      <phone>0148036222</phone>
      <email>cvignal@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric LAMIREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pia ORTHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe GAIN, MD</last_name>
      <phone>0477127793</phone>
      <email>philippe.gain@univ-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire GUILLEMOT, MD</last_name>
      <phone>0673169519</phone>
      <email>claire.guillemot@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles THURET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

